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Sporadic small vessel disease (SVD) has high prevalence in aging population and stroke patients, but 
also in younger asymptomatic subjects. in this last group it can represents a prelude to stroke and 
cognitive impairment. Still nowadays, its pathogenesis is unclear. 35 consecutive patients with SVD at 
brain MRI and 35 age- and sex-matched controls, between January 2016 and February 2018, underwent 
an extended screening for thrombophilia, autoimmunity and evaluated levels of blood markers of 
inflammation and endothelial activation. Asymmetric DiMethyl Arginine (ADMA) levels proved higher in 
patients (70.44 ± 36.25 ng/ml vs. 46.58 ± 30.67 ng/ml; p = 0.004), also after controlling for confounding 
factors. ADMA levels showed positive correlation with fazekas score (r = 0.304; p = 0.01). ROC curve 
analysis showed a moderate accuracy in discriminating patients and controls (AUc = 0.70; CI 0.57–0.82; 
p = 0.004): a cut-off of 46 ng/ml is associated with 80% sensitivity, but limited (54%) specificity. Higher 
ADMA levels characterize selected subjects with sporadic SVD, asymptomatic for vascular diseases and 
without latent inflammatory conditions or coagulopathy. This reinforces the hypothesis of the key role 
of endothelial dysfunction in SVD. Further studies should explore the cause-effect relationship between 
ADMA pathway and SVD.
Small vessel disease (SVD) refers to a group of pathological processes with various aetiologies involving perfo-
rating cerebral arterioles, venules and capillaries, resulting in damage of cerebral white and deep grey matter. It 
includes lacunas, recent small subcortical infarcts, white-matter hyperintensities (WMH), perivascular spaces 
(PVS), micro bleeds (MB) and brain atrophy1. Several Authors refer to the most common form as the so-called 
“age-related SVD”, that is considered to be related to physiological ageing and classical vascular risk factors2.
Although in early phases SVD could be asymptomatic, the LADIS (Leukoaraiosis And DIsability Study) study 
group demonstrated its large health burden: severe clinical pictures more than double the risk of transition from 
an autonomous to a dependent status after 3 years of follow-up3,4; SVD is a premorbid condition in about the 20% 
of all strokes and about 45% of dementias; in older people it is related to gait disorders, mild cognitive impairment 
and depressive symptoms4. The increasing clinical use of cerebral MRI, even in the instrumental evaluation of 
benign neurologic complaints (headache, dizziness and vertigo, nonspecific cognitive or mood disorders), has 
led to apparently incidental finding of SVD also in young people, without classical vascular risk factors, familial 
history of vascular disease or suffering from chronic inflammatory disorders.
In order to clarify SVD pathogenesis, numerous biomarkers of coagulation, inflammation and endothelial 
dysfunction have been studied, but often with discordant results. Thus, different pathogenetic hypothesis are still 
under debate5. This might derive from the clinical heterogeneity of samples and from differences in the selection 
of biomarkers that were the object of the different studies in this field. In fact, several studies examined selectively 
biomarkers of fibrinolysis, coagulation, inflammation or nitric oxide pathway and only few evaluated all of them 
in a highly selected population6.
1Department of Neuroscience, S. Maria della Misericordia University Hospital, Udine, Italy. 2Department of 
Laboratory Medicine, S. Maria della Misericordia University Hospital, Udine, Italy. 3Department of Medical Area 
(DAME), University of Udine, Udine, Italy. Correspondence and requests for materials should be addressed to F.J. 
(email: francesco.janes@gmail.com)
Received: 23 January 2019
Accepted: 4 September 2019
Published: xx xx xxxx
open
2Scientific RepoRtS |         (2019) 9:14207  | https://doi.org/10.1038/s41598-019-50778-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
In order to avoid these selection limitations, we tried to investigate different pathways implicated in SVD 
pathogenesis (inflammation, coagulation and endothelial dysfunction) in a selected homogeneous population 
of patients with WMH, who did not present significant vascular risk factors or other neurological disorders 
and were relatively young in the context of cerebrovascular disease epidemiology7–9. Among the different bio-
markers that have been investigated, only Asymmetric DiMethyl Arginine (ADMA), an endogenous inhibitor of 
endothelial nitric oxide synthase that has been linked in several studies to endothelial damage and cardiovascular 
diseases10, displayed significantly higher levels in patients than in controls.
Results
We enrolled 35 patients and 35 age and sex-matched controls. Baseline characteristics of the all sample are 
summarized in Table 1. None of the control subjects took antiplatelet agents, while 5 patients were treated with 
Acetylsalicylic Acid at the time of our evaluation. Moreover, 12 other patients and 4 controls were treated with 
statins, antihypertensive drugs and/or vitamin B supplementation. General Practitioners or other specialists had 
prescribed these drugs as part of primary vascular prevention strategy.
Biomarkers. Patients and controls did not differ in any of the haemostatic biomarkers under study (patients 
vs. controls respectively): Fy (304,0 ± 69,1 vs. 304,0 ± 86,4; mg/dl; p = 0,99), tPA (6,3 ± 3,9 vs. 6,3 ± 2,3; ng/ml; 
p = 0,98), WVF-antigen (126,7 ± 43,9 vs. 123,9 ± 46,3; %; p = 0,80), WVF-activity (102,7 ± 33,1 vs. 100,5 ± 36,2; 
%; p = 0,80), PAI (7,5 ± 4,5 vs. 9,5 ± 6,6; ng/ml; p = 0,18), PAF-AH (18,5 ± 5,2 vs. 18,8 ± 2,9; nmol/min/ml; 
p = 0,84).
No difference was found also in CRP levels (2,3 ± 4,8 vs. 2,2 ± 3,4; mg/l; p = 0,92), IL10 (0,53 ± 1,1 vs. 
0,27 ± 0,2; pg/ml; p = 0,42), Hcy (11,3 ± 3,0 vs. 12,2 ± 2,9; micromol/l; p = 0,24), NO levels (22,6 ± 13,9 vs. 
22,7 ± 11,8; µM; p = 0,99).
We did not find any significant difference also in adhesion molecules plasma levels (patients vs. controls 
respectively): ICAM (217,7 ± 41,2 vs. 213,8 ± 49,5; ng/ml; p = 0,83), VCAM (561,7 ± 175,1 vs. 572,2 ± 208,7; ng/
ml; p = 0,89), E-selectin (37,7 ± 16,3 vs. 31,7 ± 13,6; ng/ml; p = 0,33), P-selectin (19,9 ± 0,9 vs. 20,1 ± 1,0; ng/ml; 
p = 0,50).
We found significantly higher ADMA plasma levels in patients than in controls (70,44 ± 36,25 ng/ml vs. 
46,58 ± 30,67 ng/ml; p = 0,004), and ADMA plasma levels presented a significant association with the presence 
of WMH, also after controlling for possible confounding factors in a multiple logistic regression model (Table 2).
Moreover, ADMA levels did not correlate with age (r = 0,393; p = 0,11) or with homocysteine levels. In 
contrast, ADMA levels showed a positive significant, although limited, correlation with the total Fazekas score 
(r = 0,304; p = 0,01) (Fig. 1).
We found an important difference as regards to sex, since the difference in ADMA levels between patients and 
controls resulted more accentuated in males than in females (86,0 vs. 32,4; p = 0,007 and 67,2 vs. 49,5; p = 0,05 
Patients Controls p-value
N = 35 N = 35
χ2 test or Fisher 
exact test
Average (standard 
deviation), or Number (%)
Average (standard 
deviation), or Number (%)
Age (years) 51,1 (±9,3) 51,00 (±9,47) 0,96
Sex (M) 6 (17,1%) 6 (17,1%) 1,00
BMI 24,4 (±3,6) 24,2 (±4,1) 0,73
Smoke 11(31,4%) 8 (24,3%) 0,72
Alcohol abuse (≥2 unit/d) 0 (0,0%) 0 (0,0%) —
Alcohol consumption (≤1unit/d) 15 (50,0%) 10 (30,3%) 0,14
Total Cholesterolemia (mg/dl) 214,7(±30,0) 198,6 (33,2%) 0,10
Creatinine (mg/dl) 0,79 (±0,11) 0,85 (±0,14) 0,09
Hypertension 7 (20.0%) 4 (11.4%) 0,29
Homocysteine (micromole/l) 11.45 (±3.08) 12.09 (±3.91) 0,86
Migraine 20 (57.1%) 13 (37.1%) 0,21
Drugs
1. Antiplatelet agents 5 (14,3%) 0 (0%)
2. Statins 4 (11,4%) 1 (2,9%)
3. Antihypertensive 6 (17,1%) 2 (5,7%)
4. Folate and B12 vitamins 2 (5,7%) 1 (2,9%)
Time from MRI to visit (months) 10,2 (±9,5) 8,6 (±9,6) 0,57
Fazekas score
5. Total 2,69 (±1,12) 0 —
6. Periventricular 1,12 (±0,67) 0 —
8. Deep white matter 1,64 (±0,70) 0 —
Table 1. Patients and Controls baseline characteristics.
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respectively; see Fig. 2). This different behaviour did not appear to be dependent on the menopausal status, since 
either in pre-menopausal and in post-menopausal women, ADMA levels tended to be higher in patients than in 
controls, although no significant difference was found (Fig. 3). ROC curve analysis shows an overall moderate 
sensitivity in discriminating patients and controls (AUC = 0,70; CI 0,57-0,82; p = 0,004); a cut-off of 46 ng/ml is 
associated with 80% sensitivity, but limited (54%) specificity. Separating males from females is possible to observe 
that in men the performance was more impressive (Fig. 4; AUC = 0,89; CI 0,67-1,10; p = 0,025); when setting the 
cut-off at 76 ng/ml, we obtained 83% sensitivity and 100% specificity. However, the small number of males should 
suggest considering with caution these result.
Discussion
In this study we present a large laboratory assessment, which explore the different possible pathogenic mecha-
nisms of WMH in cerebral small vessel damage: alterations in coagulation and fibrinolysis processes, inflamma-
tory and autoimmune disorders, endothelial dysfunction. Several studies have already considered SVD, mainly 
in subjects displaying other vascular classical risk factors and including even strokes and Transient Ischemic 
Attacks or cardiovascular disease. The inclusion of all those confounders and conditions, which are known to 
have pathogenetic mechanisms (e.g. large vessels atherosclerosis, cardiac embolism, paradoxical embolism, 
vasospasm, vasculitis, etc.) very different from each other and from SVD in particular, appears in our opinion 
to be one of the main reasons of previous non-consistent results. In the same way, considering together all the 
SVD subtypes of lesions (WMH, perivascular enlarged spaces, brain atrophy, lacunas, microbleeds) may underlie 
different pathogenetic mechanism and might introduce further confounding factors. Among several, the few 
following evidences seem to substantiate this feeling: 1. Biomarkers evaluation in stroke setting proved to lead to 
different results according to stroke subtypes (e.g. cardioembolic vs. non-cardioembolic)11. 2. In a study analysing 
haemostatic markers of stroke recurrence (tPA, VWF and TAFI) their predictive value is consistent in coronary 
events but not in stroke12. 3. Some Authors suggest that blood biomarkers evaluation, interpretation and valida-
tion in the setting of cerebrovascular disease is highly dependent on the specific clinical setting13.
Consequently we tried to look at those patients, without clinical vascular disease (stroke in particular, but also 
heart disease and peripheral vessels disease), inflammatory brain disease (multiple sclerosis above all), who reach 
neurological evaluation for different complaints and in whom standard MRI examination reveals established 
features of SVD, such as WMH and PV hyperintesities.





ADMA 0,027 0,009 0,002* 1,027 1,010 1,045
Hypertension 0,978 0,736 0,184 0,376 0,089 1,592
Smoke 0,412 0,617 0,504 0,662 0,198 2,219
Alcohol 1,190 0,582 0,041 0,304 0,097 0,951
COSTANT 0,267 0,944 0,777 — — —
Table 2. Multiple logistic regression model, testing ADMA levels, after controlling for hypertension (history 
of), Smoke habit (former or active smoker) and alcohol consumption (mild consumption, ≤1 unit/day); B, 
values for the logistic regression equation for predicting the dependent variable (patient status) from the 
different independent variables (log-odds units). S.E., Standard Error of B; O.R., Odds Ratio.
Figure 1. Overall correlation between ADMA levels and the Fazekas Score.
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Migraine is the most common condition associated with detection of WMH, but many other syndromes 
or single symptoms are represented: tension-type headache as well, vertigo and dizziness, mood disorders, 
non-specific cognitive complaints. The association between SVD and migraine is well known14 and almost 60% of 
our patients suffered from migraine. However, the few epidemiological studies do not provide specific data on the 
relationship between the occurrence of WMH and other SVD features on one side and migraine or other medical 
conditions on the other side14: consequently, we cannot exclude the possibility that a selection bias in MRI pre-
scriptions could have led to a higher representation of migraneous subjects in our sample and in previous studies.
The panel of biomarkers we analysed was chosen after a review of the current literature (last update January 
2016) on the most reliable biomarkers already tested. Poggesi et al.6 reported in 2015 a comprehensive overview 
of these biomarkers in the setting of SVD. Our results underline, in a subset of young (mean age 49,9 +/− 10.1), 
Figure 2. ADMA plasma levels in patient males and females versus the respective controls.
Figure 3. ADMA levels in plasma, in females, according to menopausal status. Data was obtained from 31 
premenopausal (16 patients and 15 controls) and 26 postmenopausal women (12 patients and 14 controls).
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asymptomatic and with low burden of vascular risk factors (66,7% completely classical risk factor free) patients, 
the absence of evidence of latent inflammatory and autoimmune disease, as well as of coagulopathies. As far as the 
latter conditions are concerned, we actually did not looked in this study more deeply at other factors such as fac-
tor VII and VIII levels, or at the possible status of mutation carriers for Leiden, MTHFR, protrombine G20210A, 
etc. However, none of the subjects had a personal history of venous thrombosis or a family history of vascular 
disease. ADMA level seems to be the only significant marker in our panel, suggesting that endothelial dysfunction 
could play a pivotal role in asymptomatic SVD.
ADMA is one of the results of methylated proteins degradation. Differently to the others products, ADMA 
displays a unique inhibitor effect on endothelial nitric oxide synthase and leads to reduced levels of nitric oxide 
and consequently to possible endothelial dysfunction. Its plasma levels depend on some factors such as dietary 
habits, renal function and dimethylaminohydrolase (DDAH) activity10. Some studies have reported high ADMA 
concentrations in people with coronary and peripheral artery disease, chronic heart failure and pulmonary hyper-
tension, pre-eclampsia and stroke15–23. ADMA levels are reported to be higher also in genetic conditions, such 
as CADASIL24. ADMA seems also to affect cerebral vascular compliance: in a double blind, placebo-controlled 
clinical study, Kielstein et al. demonstrated that i.v. injection of exogenous ADMA in 20 healthy volunteers, lead 
to a decrease of the cerebral blood flow compared to the placebo group, without modification of systemic blood 
pressure25. N.O. levels themselves are not reduced in our patients and no correlation is present between ADMA 
levels and NO levels: however they were determined in peripheral plasma and without controlling for several 
interfering factors, thus we suggest that this result was hard to interpret in the specific setting of our study and 
should be further explored. Altogether these data suggest that ADMA and nitric oxide pathway might be a com-
mon pathogenic point in different aetiologies of early phases of cerebral SVD. However, in the majority of the 
studies we reviewed in which higher ADMA levels were associated with SVD26–30, patients had stroke or at least 
several vascular risk factors and pro-atherosclerotic conditions, such as increased age, hypertension, hypercholes-
terolemia, diabetes mellitus, insulin insensitivity, hyper-homocysteinemia, etc. leading to an unclear relationship 
between ADMA levels and other factors.
The strength of our study is the highly selected subset of patients, but it has also some limitations, first of all the 
small sample size caused by the rigorous screening itself. Although unlikely because of absence of systemic signs 
or symptoms and familiar history, we didn’t perform genetic analysis to exclude hereditary diseases or heterozy-
gous carriers status associated with sporadic SVD (e.g. CADASIL, CARASIL, MELAS, Fabry Disease, COL4A1/2 
polymorphisms and other hereditary collagenopathies). We evaluated only WMH and no other features of SVD: 
patients had no lacunas or brain atrophy, but microbleeds and superficial siderosis, which could hint at brain 
vessels amyloidosis31 although unlikely in our young sample, are detected in MRI through GRE/SWI sequences, 
not performed as often as T2/Flair ones in routine MRI examinations.
conclusions and further developments
This study suggests an association between ADMA levels and WMH in early, asymptomatic SVD. The large panel 
of biomarkers investigated seems reliably to exclude inflammatory or coagulation/fibrinolysis disorders in these 
patients and reinforces the idea that endothelial dysfunction could have a pivotal role in early SVD pathogenesis. 
It will be important to perform serial MRI to follow-up progression of WMH and serial ADMA levels as well to 
assess inter and intra-assay variability of ADMA measurement. Future in vitro studies should assess the possible 
causal link between ADMA, endothelial dysfunction and SVD; further clinical studies should on the other hand 
focus on selected groups of patients.
If confirmed, the hypothetical pathogenetic role of ADMA pathway could open interesting perspectives, both 
from the diagnostic and the therapeutic point of view.
Materials and Methods
Study design. This is a prospective case-control study. Patients were enrolled consecutively in the neurologi-
cal outpatient clinic of our Institution. Matching was used, for both age and gender, after each patient enrolment.
Figure 4. ROC cure analysis; from the left, in all (AUC = 0,70; CI 0,57-0,82 p = 0,004), female (AUC = 0,65; CI 
0,51-0,78 p = 0,043) and male (AUC = 0,89; CI 0,67-1,10 p = 0,025) subjects respectively.
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Our local ethic committee (Institutional Review Board of the Department of Medical Area, University of 
Udine) approved the study protocol (approval number 46/IRB/_gigli_16). Both patients and controls were 
enrolled after a written informed consent. Patients’ enrolment, handling and management of biological specimens 
and of subjects’ data were all performed in accordance with the relevant guidelines and regulations.
Study population. Patients and controls were enrolled between January 2016 and February 2018. Patients 
attended our clinic for several complaints (see Suppl. Table) among which the most common were migraine, 
paraesthesia, dizziness, vertigo and subjective focal symptoms.
The inclusion criteria for patients were: (i) age between 18 and 65 years; (ii) white matter hyperintensities on 
T2-weighted/fluid attenuation inversion recovery (FLAIR) sequences at brain MRI performed with high field 
equipment (1,5 T), defined using STRIVE consensus1 and categorized by Fazekas score32. An expert neurologist 
who evaluated axial-FLAIR imagines of brain MRI calculated WMH scoring.
The exclusion criteria were: (i) two or more of the classical cerebrovascular risk factors (hypertension, dia-
betes, hypercholesterolemia, smoke), (ii) history of alcohol or drug abuse, (iii) extracranial carotid disease or 
panvasculopathy, (iv) history of ischemic heart disease, (v) thrombophilia (except hyper-homocysteinemia 
and heterozygous MTHFR gene mutation) (vi) symptomatic stroke, haemorrhage, transient ischemic attack or 
other neurologic disorders (dementia, epilepsy, multiple sclerosis, brain trauma, perinatal brain injury, neuro-
degenerative diseases), (vii) rheumatologic diseases (rheumatoid arthritis, vasculitis, connectivopathy), (viii) 
recent infection or surgery, (ix) malignancies, (x) chronic use of steroids, immunosuppressive or nonsteroidal 
anti-inflammatory drugs.
The control subjects were identified among people attending our Hospital for a brain MRI, who finally dis-
played a normal scanning and in which other neurological, vascular and chronic inflammatory diseases were 
excluded in a clinical interview.
All the clinical data were collected through a face-to-face interview with a neurologist, using a structured 
questionnaire which included: age, sex, weight and height, chronic pharmacological treatments, concomitant 
and previous diseases, hypercholesterolemia, history of hypertension, hyperhomocysteinemia, detection of 
patent foramen ovale, history of migraine, familiarity for cardio-cerebrovascular diseases, menopausal status. 
All patients and controls underwent to a general and neurological examination and to neck vessels ultrasound 
examination.
Laboratory assessment. Both patients and controls underwent to the same blood drawing and analy-
sis protocol. Blood samples were drawn between 08.00 a.m. and 11.00 a.m. (mean time 9:46 a.m. ± s.d. 52′ for 
patients and time 9:19 a.m. ± s.d. 52′ for controls), in order to limit as much as possible differences imputable to 
the circadian rhythm of biomarkers expression. Plasma or serum samples were kept on ice and aliquoted into 500 
microL tubes to be stored at −80 °C until required.
An extended screening for thrombophilia and autoimmunity was conducted. In particular, anti-nuclear anti-
body (ANA), anti-extractable nuclear antigen (ENA), lupus anticoagulant (LAC), anti-cardiolipin IgG/IgM anti-
bodies, anti-beta2 glycoprotein I IgG/IgM antibodies, anti-phosphatidylserine/prothrombin IgG/IgM antibodies, 
anti-thrombin III, protein C, protein S, fibrinogen (Fy), plasminogen activator inhibitor – 1 (PAI-1), tissue plas-
minogen activator (tPA), von Willebrand factor, homocysteine, C-reactive protein (CRP) were assessed using 
diagnostic assays.
In addition, we analysed levels of blood markers of inflammation and endothelial activation. Platelet activat-
ing factor-acetyl hydrolase (PAF-AH) and nitric oxide (NO) were measured by a colorimetric assay (Cayman 
Chemical – Michigan, US). Enzyme-linked immunoassays (ELISA) were used to measure levels of interleukin 
10 (IL10) (Life Technologies, CA, US), E-selectin, P-selectin (R&D System, Minneapolis, US) and asymmetrical 
dimethyl-arginine (ADMA) (Casabio, Texas, US) following the manufacturers’ instructions. Serum concentration 
of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) were assayed 
by multiplex magnetic bead immunoassay (Bio-rad, California, US) according to the manufacturer’s instructions.
Statistical analyses. Data are reported as mean ± standard deviation for continuous variables and fre-
quency (%) for categorical variables. Case and control groups were compared using Student’s t test for continuous 
variables, while chi-square test were used for categorical data. Relationships between some variables were ana-
lysed by Pearson r correlational coefficient. The discriminative cut-off of significant variables values was evaluated 
by receiver-operating characteristic curves analysis and the predictive value was expressed as the area under the 
receiver operating characteristic curve.
All probability values are 2-tailed. A significance level of P < 0.05 was used for hypothesis testing.
Based upon the pilot analysis of 12 plasma samples tested for the extended screening specified in ‘Laboratory 
assessment’ and ADMA we determined that the standard deviation of ADMA levels (ng/ml) was 36,8 and the 
mean was 99.1. A sample of 25 patients provided 80% power to detect a one standard deviation difference in the 
normalized value of ADMA levels between patients and controls.
Statistical analyses were conducted with and SPSS 20 (SPSS Inc., Chicago USA).
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